Cargando…

The effects of concurrent oral paliperidone or risperidone use with paliperidone long-acting injection

INTRODUCTION: Dosing recommendations for paliperidone long-acting injectable antipsychotic (LAIA) do not include oral antipsychotic (OAP) overlap; however, OAPs are often given concurrently despite limited evidence describing both the risks and benefits of this practice. METHODS: A retrospective cha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stump, Trevor A., Nelson, Leigh Anne, Liu, Yifei, Kriz, Carrie R., Iuppa, Courtney A., Diefenderfer, Lauren A., Lang, Shelby E., Elliot, Ellie S. R., Sommi, Roger W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	College of Psychiatric & Neurologic Pharmacists 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7800326/ https://www.ncbi.nlm.nih.gov/pubmed/33505820 http://dx.doi.org/10.9740/mhc.2021.01.012

Ejemplares similares

Comparative Pharmacology of Risperidone and Paliperidone
por: Corena-McLeod, Maria
Publicado: (2015)

Determination of Plasma Concentration Reference Ranges for Risperidone and Paliperidone
por: Korell, J, et al.
Publicado: (2017)

Antipsychotic factors related to time to competency for forensic inpatients in a state psychiatric facility
por: Lemons, Amber, et al.
Publicado: (2022)

Enhancing Outcomes: Acceptability of Medication Formulations for the Treatment of Acute Agitation in a Psychiatric Population
por: Walker, Rachel E., et al.
Publicado: (2022)

Audit on prolactin monitoring for patients on oral risperidone, intramuscular risperidone, and intramuscular paliperidone
por: Bader, Mohamed
Publicado: (2021)

Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
por: Alphs, Larry, et al.
Publicado: (2013)

Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate
por: Patel, Charmi, et al.
Publicado: (2019)

Evidence based administration of risperidone and paliperidone for the treating conduct disorder
por: Ghanizadeh, Ahmad
Publicado: (2013)

Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis
por: Turkoz, Ibrahim, et al.
Publicado: (2011)

PM409. Paliperidone Palmitate 3-Monthly vs. 1-Monthly Injectable in Schizophrenia Patients with or without Prior Exposure to Oral Risperidone or Paliperidone
por: Mathews, Maju, et al.
Publicado: (2016)

S56. SWITCHING FROM RISPERIDONE TO PALIPERIDONE PALMITATE IN SCHIZOPHRENIA: CHANGES IN COGNITIVE FUNCTION
por: Tost Bonet, Meritxell, et al.
Publicado: (2020)

Paliperidone Palmitate versus Risperidone Long-Acting Injectable in Patients with Schizophrenia: A Meta-Analysis of Efficacy and Safety
por: Zhao, Mingjun, et al.
Publicado: (2023)

Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database
por: Voss, Erica A., et al.
Publicado: (2015)

Assessment of pharmacy student attitudes and beliefs toward patients with mental illnesses on inpatient psychiatric units
por: Diefenderfer, Lauren A., et al.
Publicado: (2020)

Dosing strategies for switching from oral risperidone to paliperidone palmitate: Effects on clinical outcomes
por: Hsia, Stephanie L., et al.
Publicado: (2018)

Assessing the understandability, actionability, and quality of online resources for the self-management of bipolar disorder
por: Sutera, Nathan D., et al.
Publicado: (2022)

Publication rates and characteristics of PGY2 psychiatric pharmacy resident research projects
por: Antley, Dayton L., et al.
Publicado: (2023)

Are the Long-Acting Intramuscular Formulations of Risperidone or Paliperidone Palmitate Associated with Post-Injection Delirium/Sedation Syndrome? An Assessment of Safety Databases
por: Alphs, Larry, et al.
Publicado: (2011)

Effects of Risperidone and Paliperidone on Brain-Derived Neurotrophic Factor and N400 in First-Episode Schizophrenia
por: Wu, Rong-Qin, et al.
Publicado: (2018)

Tachycardia during Treatment with Risperidone and Paliperidone Palmitate in a Patient without Previous Cardiovascular Disease
por: Orlins, Zachary, et al.
Publicado: (2021)

Healthcare Resource Utilization and Costs Among Patients With Schizophrenia Switching From Oral Risperidone/Paliperidone to Once-Monthly Paliperidone Palmitate: A Veterans Health Administration Claims Analysis
por: Patel, Charmi, et al.
Publicado: (2020)

Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics
por: Schreiner, A, et al.
Publicado: (2015)

Comparison of Paliperidone Palmitate and Risperidone Long-Acting Injection in Schizophrenic Patients: Results From a Multicenter Retrospective Cohort Study in France
por: Limosin, Frédéric, et al.
Publicado: (2018)

Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation
por: Corbeil, Olivier, et al.
Publicado: (2022)

Alternative initiation regimen of paliperidone palmitate long-acting injectable
por: Menendez Gil, I.E., et al.
Publicado: (2022)

A comparison of the metabolic side-effects of the second-generation antipsychotic drugs risperidone and paliperidone in animal models
por: Boyda, Heidi N., et al.
Publicado: (2021)

Accidental Overdose of Paliperidone Palmitate
por: Ojimba, Chiedozie, et al.
Publicado: (2019)

Paliperidone to Treat Psychotic Disorders
por: Minwalla, Hormazd D., et al.
Publicado: (2021)

The use of concurrent long-acting injectable antipsychotic therapy with paliperidone palmitate and aripiprazole monohydrate in a patient with schizophrenia
por: Evernden, Christopher, et al.
Publicado: (2021)

Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial
por: Takekita, Yoshiteru, et al.
Publicado: (2016)

Serum Concentrations of Paliperidone After Administration of the Long-Acting Injectable Formulation
por: Helland, Arne, et al.
Publicado: (2017)

Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia
por: Brasso, Claudio, et al.
Publicado: (2017)

Pharmacokinetic-Pharmacodynamic Modeling of the D(2) and 5-HT(2A) Receptor Occupancy of Risperidone and Paliperidone in Rats
por: Kozielska, Magdalena, et al.
Publicado: (2012)

Comparison of Capillary and Venous Plasma Drug Concentrations After Repeated Administration of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole
por: Remmerie, Bart, et al.
Publicado: (2016)

Randomized Controlled Trial of Paliperidone Extended Release Versus Risperidone for the Treatment of Methamphetamine-Associated Psychosis in Chinese Patients
por: Wang, Gang, et al.
Publicado: (2020)

Assessment of risk factors of treatment discontinuation among patients on paliperidone palmitate and risperidone microspheres in France, Germany and Belgium
por: Cai, Rui, et al.
Publicado: (2022)

Is paliperidone palmitate more effective than other long-acting injectable antipsychotics?
por: Patel, R., et al.
Publicado: (2018)

Manic Symptoms during a Switch from Paliperidone ER to Paliperidone Palmitate in a Patient with Schizophrenia
por: Demirci, Kadir, et al.
Publicado: (2015)

Catatonia Associated with Initiating Paliperidone Treatment
por: McKeown, Nathanael J., et al.
Publicado: (2010)

Rebound Catatonia Associated With Injectable Paliperidone
por: Johnson, Bamidele O, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_er8sc91qhsqnn92fsq51e4l7rj